| Income statement (USD) | FY 2025 ended Mar 31, 2025 | FY 2024 ended Mar 31, 2024 | FY 2024 ended Mar 31, 2023 |
|---|---|---|---|
| Research and development | 342.2K | 954.6K | 1.61M |
| Interest expense | 9.3K | 52.9K | |
| Net income | 1.01M | -51.16M | -3.21M |
From Psyence Biomedical Ltd.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read income statement or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.